Key symptom domains to be assessed in fibromyalgia (outcome measures in rheumatoid arthritis clinical trials)

Ernest H Choy; Philip J Mease

doi:10.1016/j.rdc.2009.05.002

Key symptom domains to be assessed in fibromyalgia (outcome measures in rheumatoid arthritis clinical trials)

Rheum Dis Clin North Am. 2009 May;35(2):329-37. doi: 10.1016/j.rdc.2009.05.002.

Authors

Ernest H Choy¹, Philip J Mease

Affiliation

¹ Sir Alfred Baring Garrod Clinical Trials Unit, Academic Department Rheumatology, Weston Education Centre, King's College London, Cutcombe Road, London, UK. [email protected]

PMID: 19647146
DOI: 10.1016/j.rdc.2009.05.002

Abstract

This article discusses the key symptom domains to be assessed in fibromyalgia. Development of a consensus on a core set of outcome measures that should be assessed and reported in all clinical trials is needed to facilitate interpretation, pooling, and comparison of results. This aligns with the key objective of the Outcome Measures in Rheumatoid Arthritis Clinical Trials initiative to improve outcome measurement in rheumatic diseases through a data-driven interactive consensus process.

Publication types

Review

MeSH terms

Arthritis, Rheumatoid / therapy
Clinical Trials as Topic / methods*
Delphi Technique
Fibromyalgia / physiopathology*
Fibromyalgia / therapy*
Focus Groups
Humans
Treatment Outcome